 SOUTH SAN FRANCISCO, Calif., Aug. 2, 2021 PRNewswire -- Vaxart, Inc., NASDAQ: VXRT, a clinical-stage biotechnology company developing oral vaccines administered by tablet, announced today that the U.S. Food and Drug Administration has cleared Vaxarts Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. 